Navigation Links
PET scan distinguishes Alzheimer's from other dementia
Date:11/1/2007

SALT LAKE CITY A PET scan (positron emission tomography) that measures uptake of sugar in the brain significantly improves the accuracy of diagnosing a type of dementia often mistaken for Alzheimers disease, a study led by a University of Utah dementia expert has found.

The scan, FDG-PET, helped six doctors from three national Alzheimers disease centers correctly diagnose frontotemporal dementia (FTD) and Alzheimers in almost 90 percent of cases in the studyan improvement of as much as 14 percent from usual clinical diagnostic methods. FDG stands for fluorodeoxyglucose, a short-lived radioactive form of sugar injected into people during PET scans to show activity levels in different parts of the brain. In Alzheimers, low activity is mostly in the back part of the brain; in FTD, low activity is mostly in the front of the brain.

FDG-PET is an especially powerful tool in early treatment of FTD, said the studys lead author, Norman L. Foster, M.D., professor of neurology and director of the Center for Alzheimers Care, Imaging and Research at the University of Utah School of Medicine.

FTD is a common cause of early onset dementia among people 45-64 years old and is marked by behavioral changes and language difficulties. Like Alzheimers, it can take years to develop and, for now, is incurable. Although FTD is a separate disorder, it often meets clinical diagnostic criteria for Alzheimers and often is misdiagnosed even by dementia experts.

Early diagnosis of FTD can have a tremendous impact on the treatment for patients and their family members. Many patients are misdiagnosed and may be hospitalized and receive drugs for the wrong disease, Foster said. Accurate diagnosis bypasses the costs, side-effects, and frustration of misguided care. Furthermore, one-third of FTD patients have a family history of a similar disorder and family members need to know if they are at increased risk of the disease.

The study was funded by the National Institute on Aging, a part of the National Institutes of Health.

Dr. Fosters work involving patients from several NIA-sponsored Alzheimers Disease Centers advances the use of PET imaging as a clinical tool, said Creighton Phelps, Ph.D., program director of the Alzheimer Disease Centers at the National Institute on Aging. Combined with the patients medical history and psychometric testing, it enhances a physicians ability to more accurately distinguish between FTD and early-onset AD.

As the U.S. population ages, the number of people with dementia is projected to increase markedly, with Utah and the Intermountain West expected to experience the fastest rate of growth. Although FDG-PET is widely available, it is not often used in dementia, because of insurance concerns. Medicare recently agreed to pay for FDG-PET scans to evaluate dementia, but currently many insurance companies in the Intermountain West and Utah do not. Foster is working to make FDG-PET scans available to those who need them and results of this study prove they sometimes are worth doing.

This study shows FDG-PET is a reliable and valid diagnostic test that can aid physicians in making the sometimes difficult clinical distinction between AD (Alzheimers disease) and FTD, Foster and his co-authors wrote. But PET scans alone are not enough to confirm FTD or Alzheimers. A careful consideration of the medical history and examination will continue to be essential to dementia evaluation.

The study has appeared online in the journal Brain.

Foster and his colleagues examined the medical records and FDG-PET scans of 45 patients who later had autopsies. Microscopic examination found 31 had Alzheimers and 14 had FTD. The researchers summarized the clinical course of the disease in each patient. The expert neurologists at the NIH centers, who had 10 years to 25 years of experience, then were asked to decide what caused each patients dementia using clinical information alone or using FDG-PET images.

The experts correctly distinguished FTD and Alzheimers using only the clinical methods in 76 percent to 79 percent of the cases. Using the FDG-PET scans alone, however, the physicians correctly diagnosed the two dementias in 85 percent to 89 percent of cases. Adding FDG-PET to clinical information increased the correct diagnosis from 79 percent to 90 percent. The highest accuracy in diagnosis was achieved with SSP (stereotactic surface projection) displays, which summarize changes in brain activity and apply a statistical test to show significant areas of damage.

The PET scans also had other benefits. The researchers found in 42 percent of cases, the scans increased the experts confidence in a correct diagnosis or made them question and sometimes change an incorrect diagnosis.


'/>"/>

Contact: Phil Sahm
phil.sahm@hsc.utah.edu
801-581-2517
University of Utah Health Sciences Center
Source:Eurekalert

Related medicine news :

1. Testing genes for disease does not cause harm to children of people with Alzheimers
2. Age-Dependent Alterations Not Specific For Alzheimers Disease
3. Killing two birds (cholesterol and Alzheimers disease) with the same stone
4. Exposure To High Aluminum Levels In Tap Water Lead To Rare Form Of Alzheimers
5. Sugar variant may make a world of difference to Alzheimers disease
6. Cancer Causing Protein May Heal Alzheimers
7. GAB2-A New Alzheimers Gene Identified
8. Emotional Stress Could Be a Factor in Causing Alzheimers: Study
9. Alzheimers Incidence is Set to Quadruple by 2050
10. Reduced Oxygen to the Brain Increases Alzheimers Risk in Stroke Victims
11. Magnets to the rescue of Alzheimers patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Harris Communications, Inc., ... hearing, is bringing its latest products to the Deaf Seniors of America Conference, April ... the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and to ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... for contaminated soil, dredged material, and hazardous and non-hazardous materials announced today the ... Pennsylvania. This acquisition will add four additional processing facilities and a vast ...
(Date:3/24/2017)... New York, NY (PRWEB) , ... March 24, ... ... cross-platform campaign: “Fighting Infection,” which will spark a conversation on the current obstacles ... decrease the number of completely preventable deaths caused by these infections. , ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
Breaking Medicine Technology: